Related Experiment Video

Updated: Aug 6, 2026

In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
07:15

In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis

Published on: October 20, 2013

9.4K

Macrophage-Targeted Dextran Sulfate-Dexamethasone Conjugate Micelles for Effective Treatment of Rheumatoid Arthritis

Jiangfan Han1,2, Ren Na3, Ningning Zhao2

  • 1Lab for Bone Metabolism, Key Lab for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China.

Molecules (Basel, Switzerland)
|January 21, 2023
PubMed

Insights

New micelles target macrophages to treat rheumatoid arthritis (RA) without dexamethasone side effects. This nanomedicine approach shows promise for effective RA therapy in inflamed joints.

Area of Science:

  • Immunology
  • Nanomedicine
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and disability.
  • Activated macrophages are key drivers in RA pathogenesis, producing pro-inflammatory factors.
  • Dexamethasone (DXM) effectively treats RA but has severe long-term side effects like diabetes and osteoporosis.

Purpose of the Study:

  • To develop a novel nanomedicine for targeted RA therapy.
  • To overcome the limitations of conventional dexamethasone treatment.
  • To investigate the efficacy of DXM@DS-cad-DXM micelles in a preclinical RA model.

Main Methods:

  • Preparation of dextran sulfate-cisaconitic anhydride-dexamethasone (DXM@DS-cad-DXM) micelles.
  • Evaluation of micelle targeting specificity to scavenger receptors (SR) on macrophages using fluorescence microscopy.
  • Assessment of micelle accumulation and anti-inflammatory effects in the inflamed joints of adjuvant-induced arthritis (AIA) rats after intravenous administration.

Main Results:

  • DXM@DS-cad-DXM micelles demonstrated potent targeting of SR on activated macrophages.
  • Micelles effectively accumulated in the inflamed joints of AIA rats.
  • Significant anti-inflammatory activity was observed in the treated joints, indicating therapeutic potential.

Conclusions:

  • DXM@DS-cad-DXM micelles offer a targeted approach for RA therapy.
  • This nanomedicine strategy may mitigate the adverse effects associated with systemic dexamethasone use.
  • DXM@DS-cad-DXM micelles represent a promising nanomedicine for RA treatment.
Keywords:
dexamethasonedextran sulfatemicellesrheumatoid arthritistargeted therapy

More Related Videos

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

11.4K
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

8.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...